Researchers at the University of Pennsylvania presented first-in-human Phase I data on SynKIR-110, a “KIR-CAR” T cell therapy designed to address exhaustion seen in conventional CAR T approaches for solid tumors. The program uses a multi-chain architecture modeled on natural killer cell receptors, separating tumor recognition from activation. In a dose-escalation trial with nine patients with advanced mesothelin-expressing cancers, investigators reported a favorable safety profile and early signals of activity, including disease stabilization and one ongoing partial response in the highest-dose cohort. The study highlights a clinical rationale: keeping engineered T cells in a resting state until target engagement could reduce continuous activation and potential depletion, particularly in solid-tumor microenvironments. For biotech, KIR-CAR’s early design reinforces the pattern of next-generation CAR modifications focused on durability and solid-tumor feasibility rather than only early response rates.